Company intelligence / Profile preview

Tara Orion

Ottawa, Ontario, Canadasquintyt4e.livejournal.com ↗

Ownership: Private
Development stage: Other

Overview

Orion Biotechnology is advancing a pipeline of GPCR-targeted therapeutics for obesity and metabolic disorders, with two lead candidates against GPR75 demonstrating efficacy in preclinical studies. The company leverages its proprietary PROcisionXTM platform to rapidly generate optimized leads, aiming to move programs into clinical development efficiently.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small moleculePeptidesProtein
Industry: Biotech

Partnerships

none publicly disclosed as of June 2025

Beyond the preview

Go deeper on Tara Orion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tara Orion.

Explore the full profile